- Conditions
- Autism Spectrum Disorders
- Interventions
- Whey Protein, Rice Protein (Placebo)
- Dietary Supplement
- Lead sponsor
- Nova Southeastern University
- Other
- Eligibility
- 3 Years to 5 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 3
- States / cities
- Fort Lauderdale, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 16,003
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prader-Willi Syndrome, Hyperphagia
- Interventions
- Intranasal Oxytocin (IN-OXT), Matched Placebo
- Drug
- Lead sponsor
- Eric Hollander
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
- Interventions
- Batiraxcept, Durvalumab
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- EZN-2208, Cetuximab and Irinotecan
- Drug
- Lead sponsor
- Enzon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 35
- States / cities
- Tucson, Arizona • Alhambra, California • Bakersfield, California + 30 more
- Conditions
- Acute-graft-versus-host Disease
- Interventions
- AAT, Placebo
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • St. Petersburg, Florida • Atlanta, Georgia + 9 more
- Conditions
- Medulloblastoma, Ependymoma, Pineal Region Tumors, Choroid Plexus Tumors, Atypical/Malignant Meningioma
- Interventions
- Nivolumab, EKG, MRI Brain and/or spine, Body CT Scan, MDASI-BT, MDASI-SP
- Drug · Diagnostic Test · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Bethesda, Maryland • Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Onartuzumab, Bevacizumab, Paclitaxel, Bevacizumab Placebo, Onartuzumab Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 23
- States / cities
- Bakersfield, California • Fullerton, California • Los Angeles, California + 19 more
- Conditions
- Chronic Migraine
- Interventions
- H.P. Acthar Gel
- Drug
- Lead sponsor
- Dent Neuroscience Research Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 4
- States / cities
- Springfield, Missouri • Reno, Nevada • Amherst, New York + 1 more
- Conditions
- Graft vs. Host Disease
- Interventions
- Brentuximab Vedotin
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Columbus, Ohio
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- CINRYZE
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 8
- States / cities
- Colorado Springs, Colorado • Tampa, Florida • Chevy Chase, Maryland + 5 more
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Polatuzumab vedotin (PV), Rituximab, Hyaluronidase, Gemcitabine, Cisplatin, Dexamethasone, GCSF
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Kidney, Polycystic
- Interventions
- Lisinopril, Telmisartan, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 15 Years to 64 Years
- Enrollment
- 486 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Unresectable Melanoma
- Interventions
- Ipilimumab, Nivolumab, Lymph Node Assessment, Biospecimen Collection
- Biological · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Retinoblastoma, Retinal Neoplasm
- Interventions
- Enucleation, Vincristine, Carboplatin, Focal Therapies, External Beam Radiation, Vincristine and Topotecan, Vincristine + Carboplatin + Etoposide, vincristine, cyclophosphamide, and doxorubicin, Vincristine, Carboplatin and Etoposide, Periocular carboplatin, G-CSF
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2024
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Pulmonary Alveolar Proteinosis, Primary Disease
- Interventions
- rituximab
- Drug
- Lead sponsor
- East Carolina University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Prostate Cancer
- Interventions
- Velcade, LH-RH Agonist, Androgen Receptor Antagonists
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 4
- States / cities
- Loma Linda, California • Charleston, South Carolina • Columbia, South Carolina + 1 more
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer, Prostate Cancer
- Interventions
- Cabozantinib, Zanzalintinib, Atezolizumab, Nivolumab, Abiraterone, Prednisone, Enzalutamide
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Bay Shore, New York • Kettering, Ohio • Memphis, Tennessee + 1 more
- Conditions
- Age Related Macular Degeneration
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- The New York Eye & Ear Infirmary
- Other
- Eligibility
- 51 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obesity
- Interventions
- recombinant human growth hormone (rhGH), Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 13 Years to 21 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diffuse Intrinsic Pontine Glioma
- Interventions
- Bevacizumab, Erlotinib, Temozolomide, Radiation
- Drug · Radiation
- Lead sponsor
- Karen D. Wright MD
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Healthy Volunteers
- Interventions
- Filgrastim Hospira, US-Approved Neupogen
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Coral Gables, Florida • Jacksonville, Florida • Miami, Florida
- Conditions
- Prostate Cancer
- Interventions
- 3-D Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, Casodex, Zoladex , Lupron
- Radiation · Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Fairway, Kansas
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
- Interventions
- BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab, mFOLFOX6, BBO-10203, mFOLFIRINOX, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 665 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 12 more
- Conditions
- Breast Cancer
- Interventions
- Atezolizumab, Trastuzumab Emtansine, Placebo, Trastuzumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2034
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Buena, California • Santa Monica, California + 19 more